Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/7/1002 |
| _version_ | 1797443315028721664 |
|---|---|
| author | Ximena Aguilera Claudia González Mauricio Apablaza Paola Rubilar Gloria Icaza Muriel Ramírez-Santana Claudia Pérez Lina Jimena Cortes Loreto Núñez-Franz Rubén Quezada-Gaete Carla Castillo-Laborde Juan Correa Macarena Said Juan Hormazábal Cecilia Vial Pablo Vial |
| author_facet | Ximena Aguilera Claudia González Mauricio Apablaza Paola Rubilar Gloria Icaza Muriel Ramírez-Santana Claudia Pérez Lina Jimena Cortes Loreto Núñez-Franz Rubén Quezada-Gaete Carla Castillo-Laborde Juan Correa Macarena Said Juan Hormazábal Cecilia Vial Pablo Vial |
| author_sort | Ximena Aguilera |
| collection | DOAJ |
| description | Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access. |
| first_indexed | 2024-03-09T12:54:12Z |
| format | Article |
| id | doaj.art-af01ab779dd84578ac11fd680fd14ab4 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T12:54:12Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-af01ab779dd84578ac11fd680fd14ab42023-11-30T22:02:21ZengMDPI AGVaccines2076-393X2022-06-01107100210.3390/vaccines10071002Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from ChileXimena Aguilera0Claudia González1Mauricio Apablaza2Paola Rubilar3Gloria Icaza4Muriel Ramírez-Santana5Claudia Pérez6Lina Jimena Cortes7Loreto Núñez-Franz8Rubén Quezada-Gaete9Carla Castillo-Laborde10Juan Correa11Macarena Said12Juan Hormazábal13Cecilia Vial14Pablo Vial15Centro de Epidemiología y Políticas de Salud, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, San Carlos de Apoquindo, Las Condes, Santiago 7610658, ChileCentro de Epidemiología y Políticas de Salud, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, San Carlos de Apoquindo, Las Condes, Santiago 7610658, ChileFacultad de Gobierno, Universidad del Desarrollo, San Carlos de Apoquindo, Las Condes, Santiago 7610658, ChileCentro de Epidemiología y Políticas de Salud, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, San Carlos de Apoquindo, Las Condes, Santiago 7610658, ChileInstituto de Matemáticas, Universidad de Talca, Talca 3460000, ChilePublic Health Department, Faculty of Medicine, Universidad Católica del Norte, Coquimbo 1780000, ChileEscuela de Enfermería, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7610658, ChileInstituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7610658, ChileDepartamento de Salud Pública, Facultad de Ciencias de la Salud, Universidad de Talca, Avenida Uno Poniente #1141, Talca 3460000, ChilePublic Health Department, Faculty of Medicine, Universidad Católica del Norte, Coquimbo 1780000, ChileCentro de Epidemiología y Políticas de Salud, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, San Carlos de Apoquindo, Las Condes, Santiago 7610658, ChileCentro Producción del Espacio, Universidad de las Américas, Santiago 7500975, ChileDepartamento de Salud Pública, Facultad de Ciencias de la Salud, Universidad de Talca, Avenida Uno Poniente #1141, Talca 3460000, ChileInstituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7610658, ChileInstituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7610658, ChileInstituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7610658, ChileChile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.https://www.mdpi.com/2076-393X/10/7/1002COVID-19vaccinesSinovac CoronavacBNT162b2AZD1222ELISA |
| spellingShingle | Ximena Aguilera Claudia González Mauricio Apablaza Paola Rubilar Gloria Icaza Muriel Ramírez-Santana Claudia Pérez Lina Jimena Cortes Loreto Núñez-Franz Rubén Quezada-Gaete Carla Castillo-Laborde Juan Correa Macarena Said Juan Hormazábal Cecilia Vial Pablo Vial Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile Vaccines COVID-19 vaccines Sinovac Coronavac BNT162b2 AZD1222 ELISA |
| title | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
| title_full | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
| title_fullStr | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
| title_full_unstemmed | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
| title_short | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
| title_sort | immunization and sars cov 2 antibody seroprevalence in a country with high vaccination coverage lessons from chile |
| topic | COVID-19 vaccines Sinovac Coronavac BNT162b2 AZD1222 ELISA |
| url | https://www.mdpi.com/2076-393X/10/7/1002 |
| work_keys_str_mv | AT ximenaaguilera immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT claudiagonzalez immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT mauricioapablaza immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT paolarubilar immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT gloriaicaza immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT murielramirezsantana immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT claudiaperez immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT linajimenacortes immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT loretonunezfranz immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT rubenquezadagaete immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT carlacastillolaborde immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT juancorrea immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT macarenasaid immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT juanhormazabal immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT ceciliavial immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT pablovial immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile |